Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Programmed cell death ligand-1 immunohistochemical detection (PD-L1 IHC) is a putative predictor of response to PD-1/PD-L1-targeted checkpoint inhibitors. However, there is no gold standard assay in hepatocellular carcinoma (HCC). We evaluated 5 PD-L1 IHC assay platforms (E1LN3, 28-8, 22c3, SP263 and SP142) in 100 HCCs reporting PD-L1 expression in malignant (M) and tumour-infiltrating immune cells (TICs) and non-tumorous cirrhotic tissues (NTICs). We found substantial inter-assay heterogeneity in detecting PD-L1 expression in M ( R 2 = 0.080–0.921), TICs (Cohen’s κ = 0.175–0.396) and NTICs ( κ = 0.004–0.505). Such diversity may impact on the reliability and reproducibility of PD-L1 IHC assays as a predictor of response to immune checkpoint inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Cited by
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Self-citationQin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Zhu, A. X., Abbas, A. R., de Galarreta, M. R., Guan, Y., Lu, S., Koeppen, H., Zhang, W., Hsu, C.-H., He, A. R., Ryoo, B.-Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01868-2 · Cited by 652
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 561
Metadata
- Authors
- Pinato, D. J., Mauri, F. A., Spina, P., Cain, O., Siddique, A., Goldin, R., Victor, S., Pizio, C., Akarca, A. U., Boldorini, R. L., Mazzucchelli, L., Black, J. R. M., Shetty, S., Marafioti, T., & Sharma, R.
- Venue
- British Journal of Cancer
- Published
- 2019-05
- Volume
- 120
- Issue
- 11
- Pages
- 1033-1036
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2943041940
- Cited by
- 111
- References
- 1
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study. https://app.cochat.ai/papers/10.1038/s41416-019-0466-x
- The paper
- Pinato, D. J., Mauri, F. A., Spina, P., Cain, O., Siddique, A., Goldin, R., Victor, S., Pizio, C., Akarca, A. U., Boldorini, R. L., Mazzucchelli, L., Black, J. R. M., Shetty, S., Marafioti, T., & Sharma, R. (2019). Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study. British Journal of Cancer. https://doi.org/10.1038/s41416-019-0466-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.